← All organizations
Highest phase reached
Phase 3
Defunct as of Mar 1, 2015
Timeline
1990s
- Jun 15, 1990
technetium tc-99m mertiatide kit— NDA Secondary Org
- Jun 15, 1990
technetium tc-99m mertiatide kit— NDA Organization
2000s
- Sep 22, 2008
technetium tc-99m sestamibi— Marketing Organization
2010s
- Mar 1, 2015
Curium Pharma— Defunct
- Jun 1, 2017
Curium Pharma— Founded
- Apr 11, 2018
Cyclopharma— Acquired
Drugs by trial phase (6 distinct, 5 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (0 own, 1 via acquisition)
Marketed drugs (18)
- gallium citrate ga 67
- in111-octreoscan
- ioflupane i-123
- technetium tc-99m sestamibi
- xenon xe-133
- cu-64 dotatate
- sodium iodide i-123
- technetium tc-99m mertiatide kit
- technetium tc-99m pyrophosphate
- technetium tc-99m red blood cell kit
- ultra-technekow fm
- thallous chloride ti 201
- sodium chromate cr-51
- technetium tc-99m pentetate kit
- phosphocol p32
- sodium iodide i-131
- technetium tc-99m oxidronate kit
- indium in-111
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (4)
- NCT06235099Lead sponsorPhase 3Apr 1, 2024
- NCT06235151Lead sponsorPhase 3Apr 1, 2024
- NCT05653856Lead sponsorPhase 2Dec 31, 2022
- NCT05204927Lead sponsorPhase 3Feb 14, 2022
Details
- Founded
- Paris, FR Jun 1, 2017
- Last known activity
- Mar 26, 2025
Designations held
- Priority review